BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $874,550 | -18.8% | 23,173 | -2.0% | 0.02% | -12.5% |
| Q2 2023 | $1,077,631 | -9.2% | 23,653 | -19.2% | 0.02% | -14.3% |
| Q1 2023 | $1,187,029 | -25.8% | 29,266 | -6.8% | 0.03% | -30.0% |
| Q4 2022 | $1,600,203 | -8.9% | 31,395 | -3.7% | 0.04% | -16.7% |
| Q3 2022 | $1,757,000 | -17.0% | 32,618 | -1.1% | 0.05% | -11.1% |
| Q2 2022 | $2,118,000 | -23.3% | 32,973 | -7.4% | 0.05% | -14.3% |
| Q1 2022 | $2,761,000 | -15.2% | 35,609 | -6.1% | 0.06% | -11.3% |
| Q4 2021 | $3,254,000 | -1.8% | 37,904 | -8.0% | 0.07% | -12.3% |
| Q3 2021 | $3,313,000 | -1.6% | 41,196 | -1.5% | 0.08% | -1.2% |
| Q2 2021 | $3,367,000 | -15.1% | 41,821 | -11.1% | 0.08% | -22.6% |
| Q1 2021 | $3,966,000 | +2.9% | 47,027 | -2.1% | 0.11% | 0.0% |
| Q4 2020 | $3,853,000 | -3.3% | 48,014 | -3.1% | 0.11% | -13.8% |
| Q3 2020 | $3,984,000 | -8.1% | 49,542 | -1.6% | 0.12% | -15.2% |
| Q2 2020 | $4,333,000 | +11.7% | 50,327 | +5.3% | 0.14% | -4.6% |
| Q1 2020 | $3,879,000 | -5.7% | 47,780 | -2.8% | 0.15% | +15.2% |
| Q4 2019 | $4,112,000 | -4.8% | 49,175 | -0.4% | 0.13% | -13.2% |
| Q3 2019 | $4,320,000 | +6.4% | 49,388 | -0.4% | 0.15% | +4.1% |
| Q2 2019 | $4,062,000 | -1.8% | 49,592 | -2.5% | 0.15% | -7.6% |
| Q1 2019 | $4,137,000 | +6168.2% | 50,881 | +4988.1% | 0.16% | -18.6% |
| Q4 2018 | $66,000 | -98.3% | 1,000 | -98.0% | 0.19% | +9.6% |
| Q3 2018 | $3,945,000 | -0.0% | 51,180 | -4.2% | 0.18% | +4.7% |
| Q2 2018 | $3,946,000 | +11.5% | 53,442 | -1.7% | 0.17% | +15.8% |
| Q1 2018 | $3,538,000 | +0.5% | 54,393 | -0.2% | 0.15% | +2.8% |
| Q4 2017 | $3,522,000 | +7.8% | 54,490 | +4.7% | 0.14% | +1.4% |
| Q3 2017 | $3,267,000 | -3.9% | 52,058 | -7.2% | 0.14% | -8.5% |
| Q2 2017 | $3,398,000 | +15.1% | 56,122 | -1.4% | 0.15% | +13.3% |
| Q1 2017 | $2,952,000 | +10.8% | 56,935 | -5.2% | 0.14% | +6.3% |
| Q4 2016 | $2,664,000 | -7.9% | 60,066 | -1.1% | 0.13% | -9.9% |
| Q3 2016 | $2,891,000 | +2.0% | 60,740 | -3.1% | 0.14% | 0.0% |
| Q2 2016 | $2,834,000 | -14.8% | 62,674 | -22.6% | 0.14% | -18.5% |
| Q1 2016 | $3,327,000 | -15.7% | 80,989 | -21.7% | 0.17% | -14.8% |
| Q4 2015 | $3,947,000 | -24.5% | 103,468 | -35.0% | 0.20% | -28.3% |
| Q3 2015 | $5,229,000 | -66.0% | 159,167 | -27.7% | 0.28% | -63.1% |
| Q2 2015 | $15,389,000 | -42.9% | 220,059 | -44.1% | 0.77% | -43.1% |
| Q1 2015 | $26,959,000 | +6.3% | 393,558 | +13.8% | 1.35% | +7.3% |
| Q4 2014 | $25,352,000 | +10.9% | 345,918 | +8.6% | 1.26% | +7.2% |
| Q3 2014 | $22,863,000 | +6.3% | 318,558 | +7.1% | 1.17% | +6.0% |
| Q2 2014 | $21,506,000 | +8.9% | 297,451 | +10.9% | 1.10% | +5.7% |
| Q1 2014 | $19,740,000 | +28.3% | 268,274 | +21.3% | 1.04% | +26.8% |
| Q4 2013 | $15,385,000 | +39.1% | 221,214 | +31.4% | 0.82% | +28.5% |
| Q3 2013 | $11,059,000 | +14.7% | 168,350 | +21.0% | 0.64% | +10.7% |
| Q2 2013 | $9,640,000 | – | 139,166 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |